Pharmacological Strategies for Treatment-Resistant Schizophrenia

Introduction to this topic

Professor Thomas Barnes
Emeritus Professor of Clinical Psychiatry, Imperial College London

Updated: Tuesday, 14th November 2017
Last Checked: Tuesday, 14th November 2017 Current

Supporting Files

Supporting files for this topic are available if you have a current CPD subscription.

This topic describes the current evidence base for the effectiveness of different strategies for the pharmacological management of treatment-resistant schizophrenia. These include ensuring the adequacy of first- and second-generation drug management, the limited evidence for the effectiveness of these drugs in combination or in high-dose strategy, and when to consider moving to clozapine. The evidence for the superior clinical effectiveness of clozapine is described, as well as important pharmacokinetic interactions that impact on its benefits and risks. Finally, for patients who remain symptomatic despite clozapine, the evidence-base for next-step strategies of clozapine augmentation by other drugs is described. This includes combinations for which there is some limited evidence of effectiveness and those for which the evidence suggests a lack of effectiveness.

Back to Schizophrenia

NB you need to be logged in and your subscription must be up to date in order to view the presentations below

Sections in this Topic

Play the video for Section


Duration: 02m 59s
No. of slides: 4 - View Slide List

Play the video for Section

Non-clozapine antipsychotic strategies

Duration: 07m 50s
No. of slides: 19 - View Slide List

Play the video for Section


Duration: 09m 57s
No. of slides: 12 - View Slide List

Play the video for Section

Adjunctive treatment with non-antipsychotics

Duration: 15m 12s
No. of slides: 21 - View Slide List